Since TET2 variants were concomitantly observed with variants in NPM1, FLT3, JAK2, RUNX1, CEBPA, CBL, and KRAS in sporadic AML patients [64], we evaluated these genes in TET2-mutated AML samples. The gene discussed is KRAS; the disease is acute myeloid leukemia.